Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?

Noel Chan and John Eikelboom

Population Health Research Institute, Hamilton, Ontario, Canada and Hamilton General Hospital and McMaster University, Hamilton, Ontario, Canada

This editorial refers to ‘Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome’, by O. Miró et al. doi:10.1093/eurheartj/ehab314.

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected >180 million people globally, and the count is still rising. Although most people have mild disease and recover within a few weeks, COVID-19 has disrupted healthcare systems around the world, caused at least 3.9 million deaths, and is associated with long-term health effects, some of which are yet to be fully characterized.

The hallmarks of COVID-19 are viraemia, inflammation, hypercoagulability, and organ dysfunction. The most common clinical manifestations of hypercoagulability are venous thromboembolism (VTE) followed by stroke, myocardial infarction, and acute peripheral artery occlusion. However, autopsy studies demonstrate small vessel platelet–fibrin thrombi (microvascular thrombosis) in ~80% of cases, implicating thrombosis as a major cause of organ dysfunction and death. Mechanisms of hypercoagulability remain incompletely understood, but there is increasing evidence that a dysregulated immune response plays a central role. In the early stages of infection, SARS-CoV-2 is localized to the respiratory tract where it enters epithelial and endothelial cells via the angiotensin-converting enzyme 2 (ACE2) receptor and causes local injury. In more advanced stages, disseminated and unchecked viral replication induces widespread endothelialopathy that is accompanied by a florid maladaptive inflammatory response, increasing hypercoagulability and multiorgan dysfunction.

Case series have reported VTE in 4.8–46% of hospitalized patients with COVID-19, with the highest rates in critically ill patients admitted to the intensive care unit, often despite prophylactic anticoagulation. Furthermore, meta-analysis data suggest that COVID-19 patients with VTE have a 2.1-fold higher risk of mortality than those without VTE, prompting calls for routine use of intensified thromboprophylaxis to improve outcomes. However, it is unclear from the published data to what extent hospitalization and the use of thromboprophylaxis contributed to the observed risk of VTE, and whether preventing VTE in patients with COVID-19 improves outcomes remains unresolved.

Miró and colleagues took a different approach to many of the earlier studies by focusing their study of VTE in COVID-19 on outpatient populations. Their study, published in this issue of the European Heart Journal, included patients presenting between 1 March and 30 April 2020 to one of 62 emergency rooms that provide care to about one-third of the Spanish population. Their study has at least three important findings. First, among the 74,814 outpatient patients with COVID-19, a total of 368 were diagnosed with pulmonary embolism (PE), which is ~9-fold higher than the rate of PE in those without COVID-19 presenting during the same period (i.e. between 1 March and 30 April) in either 2019 or 2020 (standardized incidence: 310.1 vs. 34.7 per 100,000 person-years). Although the overall incidence of PE was low (~0.5%), their data highlight the importance of COVID-19 as a risk factor for PE. Second, compared with non-COVID-19 patients with PE, patients with COVID-19 and PE were less likely to have a history of VTE or to be receiving chronic oestrogen therapy, more likely to present with fever, diarrhoea or pulmonary infiltrates, and less likely to have accompanying leg pain or swelling, or a D-dimer >1000 ng/mL; and their thrombosis was less likely to involve the main pulmonary arteries, although there was no difference between groups in the proportion of patients with right ventricular dysfunction. These findings provide valuable insights into the manifestations of PE in patients with COVID-19, but it is unclear if this information will help to refine the approach to diagnosis because there was substantial overlap in the clinical presentation of COVID-19 patients with or without PE. Third, although patients diagnosed with PE in the context of COVID-19 had higher in-hospital mortality than those who were diagnosed with PE who did not have COVID-19 (16.0% vs. 6.5%), mortality in COVID-19 patients was similar irrespective of the diagnosis of PE (16.0% vs. 16.6%).

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

© The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.
Strengths of this study include focus on non-hospitalized patients, large sample size, consistency of the findings using multiple control groups, and focus on PE which is the most serious manifestation of VTE. Limitations include the potential for underestimating PE incidence because not all patients with symptoms present to emergency rooms, and not all patients who had symptoms compatible with the diagnosis were investigated for PE. It is also possible that COVID-19 patients were more likely than those without COVID-19 to undergo investigation for PE, potentially leading to higher estimates of PE rates.

Perhaps the most important insight provided by Miró and colleagues is that although the diagnosis of PE in patients with COVID-19 was associated with higher intensive care unit admission rates, it was not associated with an increased risk of death. It remains possible that the study was underpowered to detect differences in survival, but the results would be consistent with the conclusion that PE is not a modifiable risk factor for death in patients with COVID-19.

What are the implications of these findings for clinical practice? The data provided by Miró and colleagues lend further support to the importance of COVID-19 as a risk factor for VTE. At the same time, in the absence of high-quality evidence demonstrating a benefit of therapies that prevent thrombo-embolism, their finding of a lack of association between PE and death in patients with COVID-19 should prompt further caution in the routine adoption of intensified anticoagulant strategies that can increase bleeding. By reducing blood flow to the lungs, large vessel thrombo-embolism has the potential to worsen respiratory function in patients with COVID-19. However, microvascular complications may be the most important thrombo-embolic complications in these patients, and it is unclear if these can be prevented with therapeutic anticoagulation. Consistent with this conclusion, randomized trials of intensified thromboprophylaxis using intermediate or therapeutic doses of anticoagulation have so far failed to demonstrate mortality benefits in a combined total of 4470 hospitalized patients with COVID-19, despite apparently reducing major thrombosis including VTE in some trials (Table 1)12-15. More than 70 randomized trials of antithrombotic therapy are currently ongoing in patients with COVID-19, and their successful completion should help to clarify this issue.16

Conflict of interest: none declared.

References
1. John Hopkins University. COVID-19 Dashboard. https://www.arcgis.com/apps/ dashboards/bda75947044000f923467b48e9ec6 (24 May 2021)
2. World Health Organization. COVID-19 continues to disrupt essential health services in 90% of countries. https://www.who.int/news/item/23-04-2021-covid-19-continues-to-disrupt-essential-health-services-in-90-of-countries (24 May 2021)
3. Pellicori P, Doolub G, Wong CM, Lee KS, Mangion K, Ahmad M, Berry C, Squire I, Lambiase PD, Lyon A, McConnellie A, Taylor RS, Cleland JG. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev 2021;3(3):CD013879
4. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–232.
5. The Lancet. Facing up to long COVID. Lancet 2020;396:1861.
6. del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA 2020;324:1723–1724.
7. Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res 2020; 30:367–369.
8. Parra-Medina R, Herrera S, Mejia J. Systematic review of microthrombi in COVID-19 autopsies. Acta Haematol 2021doi: 10.1159/000551504.
9. Kwee RM, Adams HA, Kwee TC. Pulmonary embolism in patients with COVID-19 and value of D-dimer assessment: a meta-analysis. Eur Radiol 2021;doi: 10.1007/s00330-021-09003-8.
10. Kollas A, Kyriakoulis KG, Lagou S, Kontopantelis E, Stergiou GS, Syrigos K. Venous thromboembolism in COVID-19: a systematic review and meta-analysis. Vasc Med 2021;doi: 10.1177/1358863X21995566.
11. Miró O, Jimenez S, Melbaza A, Freund Y, Builloc-Putze G, Martín A, Martín-Sánchez FJ, Lambrechets J, Alquézar-Árbe A, Jacobi J, Llorens P, Piñera P, Gil V, Guardiola J, Cardozo C, Módo Deitell JM, Tost J, Aguirre Tejado A, Palau-Vendrell A, Llaurer García L, Aladro Muñoz M, del Arco Galán C, Agudo Villa T, López-Laguna N, López Diez MP, Beddar Chaib F, Quero Moto E, González Tejera M, Ponce MC, González del Castillo J. Spanish Investigators on Emergency Situations TeAm (SIESTA) network. Pulmonary embolism in patients

---

**Table 1 Completed trials of intensified anticoagulant therapy vs. standard dose thromboprophylaxis in hospitalized patients with COVID-19**

| Trial | COVID-19 population | Experimental treatment* | Major thrombosis | Major bleeding | Mortality |
|------|---------------------|------------------------|------------------|----------------|----------|
| NIH multiplatform trial1,2,13 ATTACCO/ ACTIV-4a/REMAP-CAP | Non-critically ill (n = 2219) | Therapeutic LMWH/UFH | 1.4% vs. 2.7b | 1.9% vs. 0.9b | 7.3% vs. 8.2% |
| | Critically ill in ICU (n = 1074) | Therapeutic LMWH/UFH | 5.7% vs. 10.3b | 3.1% vs. 2.4c | 35.7% vs. 34.7c |
| INSPIRATION14 | Critically ill in ICU (n = 562) | Intermediate dose enoxaparin (1 mg/kg daily) | 3.3% vs. 3.5%VTE | 2.5% vs. 1.4% | 43.1% vs. 40.9% |
| ACTION (NCT04394377)15 | Elevated D-dimer (n = 615) | Rivaroxaban 20 mg daily (stable patients) or enoxaparin 1 mg/kg twice daily (unstable patients) | 4.0% vs. 6.0%VTE | 3.0% vs. 1.0% | 11% vs. 8% |

ICU, intensive care unit; LMWH, low molecular weight heparin; NIH, National Institutes of Health; UFH, unfractionated heparin; VTE, venous thrombo-embolism.

*Control treatment was an approved prophylactic dose of UFH or LMWH.

bP-value or confidence interval not reported.

cNot significant.
with COVID-19: incidence, risk factors, clinical characteristics, and outcome. Eur Heart J 2021;42:3127–3142.

12. Zarychanski R; REMAP-CAP, ACTIV-4a, ATTACC Investigators. Therapeutic anticoagulation in critically ill patients with Covid-19—preliminary report. medRxiv 2021; doi:10.1101/2021.03.10.21252749.

13. Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Cariner M, Rossenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kahn SR, Cushman M, McQuilten Z, Slutsky AS, Kim KS, Gordon AC, Kirwan BA, Brooks MM, Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, Angus DC, McArthur CJ, Webb SA, Farkouh ME, Hochman JS, Zarychanski R; ATTACC, ACTIV-4a, REMAP-CAP Investigators. Therapeutic anticoagulation in non-critically ill patients with Covid-19. medRxiv 2021; doi:10.1101/2021.05.13.21256846.

14. Sadeghipour P, Talasaz AH, Rashidi F, Sharifi-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Jamalkhani S, Khalili H, Yadollahzadeh M, Raah T, Rezaeifar P, Tahamtan O, Matin S, Abedini A, Loozkhadeh S, Rahmani H, Zoghi E, Mohammadi K, Sadeghipour P, Abrin H, Tabrizi S, Mousavian SM, Shahmirzaei S, Bahkshandeh H, Amin A, Rafiee F, Baghizadeh E, Mohabbati B, Parhizgar SE, Aliannejad R, Estami V, Kashefizadeh A, Kakavand H, Hosseini SH, Shafaghi S, Ghazi SF, Najafi A, Jimenez D, Gupta A, Madhavan MV, Sethi SS, Panikh SA, Monreal M, Hadavand N, Hajihasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane AJ, Van Tassell BW, Dobesh PP, Stone GW, Lip GYH, Krumholz HM, Goldhaber SZ, Bikdeli B. INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA 2021;325:1620–1630.

15. Lopes RD, De Barros e Silva PGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, Barbosa LM, De Averno Morata J, Ramacciotto E, De Aquino Martins P, De Oliveira AL, Nunes VS, Ritti LEF, Rocha AT, Tramujas L, Santos SV, Diaz DRA, Viana LS, Melo LMG, De Alcântara Chaud MS, Figueiredo EL, Neuenschwander FC, Dracoulakis MDA, Lima RGSD, De Souza Dantas VC, Fernandes ACS, Gabara OCE, Hernandez ME, Queiroz DAR, Vega VC, Caresin MF, De Faria LM, Fellota-Filho GS, Gazzana MB, Liporace IL, De Oliveira Twardowsky A, Maia LN, Machado FR, De Matos Soeiro A, Conceição-Sousa GE, Armaganian L, Guimarães PO, Rosa KG, Azevedo LCP, Alexander JH, Avezum A, Cavalcanti AB, Berwanger O. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021;397:2253–2263.

16. Talasaz AH, Sadeghipour P, Kakavand H, Aghakouchakzadeh M, Kordzadeh-Kermani E, Van Tassell BW, Ghemyati A, Aryannejad H, Hosseini SH, Jamalkhani S, Sholzberg M, Monreal M, Jimenez D, Piazza G, Parikh SA, Kirtane AJ, Eikelboom JW, Connors JM, Hunt BJ, Constantinides SV, Cushman M, Weitz JI, Stone GW, Krumholz HM, Lip GYH, Goldhaber SZ, Bikdeli B. Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;77:1903–1921.